

5. **Zachoval R.** Mikční dysfunkce u pacientů s roztroušenou sklerózou. In: Krhut J, editor. *Neurourologie*. Praha: Nakladatelství Galén 2005; 11: 77–83.
6. **Khan F, Pallant JF, Shea TL, et al.** Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. *Disabil Rehabil* 2009; 31(19): 1567–1576.
7. **de Seze M, Ruffion A, Denys P, et al.** The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. *Mult Scler* 2007; 13(7): 915–928.
8. **Wyndaele JJ, Kovindha A, Madersbacher H, et al.** Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. *Incontinence, 4th Edition*. Plymouth: Health Publication Ltd. 2009: 793–960.
9. **Krhut J, Zapletalová O, Zachoval R, et al.** Doporučení pro diagnostiku a léčbu symptomů dolních močových cest u pacientů s roztroušenou sklerózou v České republice – mezioborový mezioborový konsenzus expertů dle metodiky DELPHI. *Cesk Slov Neurol N* 2017; 80/113(2): 233–237.
10. **Blok B, Castro-Diaz D, Del Popolo G, et al.** *Neuro-urology*. Arnhem, The Netherlands: EAU Guidelines Office; 2019.
11. **McClurg D, Ashe RG, Marshall K, Lowe-Strong AS.** Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. *Neurourol Urodyn*. 2006; 25(4): 337–348.
12. **Lucio AC, Campos RM, Perissinotto MC, et al.** Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. *Neurourol Urodyn* 2010; 29(8): 1410–1413.
13. **McClurg D, Ashe RG, Lowe-Strong AS.** Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis – a double blind, placebo controlled, randomised clinical trial. *Neurourol Urodyn* 2008; 27(3): 231–237.
14. **Fjorback MV, Van Rey FS, Rijkhoff NJM, et al.** Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. *Neurourol Urodyn* 2007; 26(4): 525–530.
15. **Centonze D, Petta F, Versace V, et al.** Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. *Mult Scler* 2007; 13(2): 269–271.
16. **Nasios G, Messinis L, Dardiotis E, Papathanasopoulos P.** Repetitive Transcranial Magnetic Stimulation, Cognition, and Multiple Sclerosis: An Overview. *Behav Neurol* 2018; doi: 10.1155/2018/8584653.
17. **De Ridder D, Ost D, Van der Aa F, et al.** Conservative bladder management in advanced multiple sclerosis. *Mult Scler* 2005; 11(6): 694–699.
18. **Krhut J, Borovicka V, Bilkova K et al.** Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. *Neurourol Urodyn* 2018; 37(7): 2226–2233.
19. **Valiquette G, Herbert J, Maede-D, Alisera P.** Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. *Arch Neurol* 1996; 53(12): 1270–1275.
20. **Odeh M, Oliven A.** Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis. *J Clin Pharmacol* 2001; 41(5): 582–584.
21. **Abo Youssef N, Schneider MP, Mordasini L, et al.** Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. *BJU Int* 2017; 119(4): 515–521.
22. **Francomano D, Ilacqua A, Cortese A, et al.** Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. *J Endocrinol Invest* 2017; 40(3): 275–279.
23. **Schroder A, Albrecht U, Schnitker J, Reitz A, Stein R.** Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. *Neurourol Urodyn* 2016; 35(5): 582–588.